NCT03242915: A reported trial by University of Michigan Rogel Cancer Center
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03242915 |
|---|---|
| Title | Phase II Study of Pembrolizumab in Combination With Platinum-based Chemotherapy in Nonsmall Cell Lung Cancer Patients With Targetable Genetic Alterations Previously Treated With Appropriate Targeted Agents With Progressive Disease |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 3, 2017 |
| Completion date | Feb. 20, 2025 |
| Required reporting date | Feb. 20, 2026, midnight |
| Actual reporting date | April 3, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |